Shoshana Shendelman, Applied Therapeutics CEO
Applied Therapeutics says rare disease drug fails PhIII trial, still plans to seek approval
Applied Therapeutics, which is developing a treatment for a rare disease that affects children who can’t process a sugar called galactose, missed the primary endpoint …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.